智通财经网·2025-12-17 11:37Core Viewpoint - Baiyunshan (600332.SH) announced that its subsidiary, Guangzhou Medicine, plans to acquire 100% equity of Zhejiang Pharmaceutical Industry Co., Ltd. from Haizheng Pharmaceutical for a transfer price of 501 million yuan [1] Group 1: Acquisition Details - The acquisition will be conducted through a public transfer process [1] - The transfer price for the acquisition is set at 501 million yuan [1] Group 2: Company and Market Position - Zhejiang Pharmaceutical is located in the Yangtze River Delta, a region with a developed pharmaceutical market, and is ranked among the top 6 quality pharmaceutical distribution companies in Zhejiang Province [1] - Over the past year, Zhejiang Pharmaceutical has achieved sales revenue exceeding 4 billion yuan, indicating a strong market presence and growth potential [1] Group 3: Strategic Implications - This transaction will enable Guangzhou Medicine to gain access to a mature customer network in Zhejiang Province and surrounding areas [1] - The acquisition aligns with the long-term strategic planning of Guangzhou Medicine to optimize its industrial layout in the East China region and enhance coverage of the domestic terminal market [1]